Survivin
Survivin is a member of the inhibitor of apoptosis (IAP) family. The survivin protein functions to inhibit caspase activation, thereby leading to negative regulation of apoptosis or programmed cell death. This has been shown by disruption of survivin induction pathways leading to increase in apoptosis and decrease in tumour growth. Survivin expression is highly regulated by the cell cycle and is only expressed in the G2-M phase. Survivin localizes to the mitotic spindle by interaction with tubulin during mitosis and may play a contributing role in regulating mitosis. Survivin is highly expressed in most cancers and associated with chemotherapy resistance, increased tumor recurrence, and shorter patient survival, making antisurvivin therapy an attractive cancer treatment strategy.
All Product Categories
-
Survivin Related Products (81)
Related Products (81)
-
Antibodies (3)
-
(2''S)-2'',3''-Dihydrodelicaflavone
0 ImagesCat. No.: HY-N18315CAS No.: 3035699-17-0(2''S)-2'',3''-Dihydrodelicaflavone is a biflavonoid compound present in the whole herb of Selaginella doederleinii, which exhibits antiproliferative and apoptosis-inducing activities against non-small cell lung cancer cells. (2''S)-2'',3''-Dihydrodelicaflavone can be used in the research of non-small cell lung cancer.
-
BKM1644
0 ImagesCat. No.: HY-119001CAS No.: 1070966-96-9BKM1644, an acyl-tyrosine bisphosphonate amide derivative, exhibits potent anti-cancer activity. BKM1644 effectively inhibits the proliferation of metastatic, castration-resistant prostate cance (mCRPC) cells. BKM1644 sensitizes mCRPC cells to Docetaxel (HY-B0011) and retards the bone metastatic growth of prostate cance.
-
AQIM-I
0 ImagesCat. No.: HY-162041CAS No.: 2247881-73-6AQIM-I is an inhibitor of survivin via inhibits survivin expression and colony formation. AQIM-I induces ROS production, apoptosis, cell cycle arrest, DNA damage, and autophagy. AQIM-I inhibits nonsmall cell lung cancer cells A549 with an IC50 value of 9 nM.
-
Entadamide A-CO-C12
0 ImagesCat. No.: HY-179615Entadamide A-CO-C12 is an Entadamide A (HY-N12125) derivative with potent anti-cancer activity, particularly against breast cancer cell lines. Entadamide A-CO-C12 promotes apoptosis, suppresses migratory ability, sphere formation, and stem-like cell populations. Entadamide A-CO-C12 inhibits tumor growth in a 4T1 mouse model. Entadamide A-CO-C12 can be used for the research of breast cancer.
-
Gataparsen
0 ImagesCat. No.: HY-177633CAS No.: 1065019-70-6Synonyms: LY 2181308Gataparsen is an antisense oligonucleotide directed against survivin mRNA with potential antitumor activity.
-
(-)-Norgestrel-d6
0 ImagesCat. No.: HY-W743417(-)-Norgestrel-d6 is the deuterium labeled Levonorgestrel (HY-B0257). Levonorgestrel is an orally active inhibitor of progesterone (HY-N0437). Levonorgestrel has anticancer activity and can induce Apoptosis. Levonorgestrel can be used as a contraceptive and in combination with other medications. Levonorgestrel can be used in the study of osteoporosis and uterine leiomyoma.
-
MX106
0 ImagesCat. No.: HY-124130CAS No.: 2170836-81-2MX106 is a survivin inhibitor and an analog of UC-112 (HY-12842). MX106 inhibits the expression of survivin both in vitro and in vivo. MX106 suppresses the proliferation of human melanoma cells, epidermoid carcinoma cells and colon cancer cells, and also exerts inhibitory effects on multidrug-resistant cell lines overexpressing P-glycoprotein.
-
(rac)-ZK-304709
0 ImagesCat. No.: HY-19471CAS No.: 1010440-84-2(rac)-ZK-304709 is an isoform of ZK-304709 and is an orally active multi-targeted tumor growth inhibitor that inhibits multiple cell cycle-dependent kinases (CDKs), vascular endothelial growth factor receptor kinases (VEGF-RTKs), and platelet-derived growth factor receptor kinase β (PDGF-RTKβ). (rac)-ZK-304709 can dose-dependently inhibit the proliferation and colony formation of neuroendocrine tumor (NET) cells. (rac)-ZK-304709 directly acts on NET cells by inducing G2 cell cycle arrest and apoptosis, while reducing the expression of MCL1, survivin, and HIF1α. (rac)-ZK-304709 effectively controls tumor growth by inducing apoptosis and inhibiting tumor-induced angiogenesis, and may become a potential agent for inhibiting NET.
-
Isonanangenine B
0 ImagesCat. No.: HY-N12173CAS No.: 1623153-14-9Synonyms: SF002-96-1Isonanangenine B (SF002-96-1) is a selective survivin inhibitor (IC50=1.6 µM). Isonanangenine B blocks the binding of key transcription factors, such as Stat3 and NF-κB, to the survivin promoter. Isonanangenine B is promising for research of cancers.
-
Gataparsen sodium
0 ImagesCat. No.: HY-177633ASynonyms: LY 2181308 sodiumGataparsen sodium is an antisense oligonucleotide directed against survivin mRNA with potential antitumor activity.
-
PBX-7011
0 ImagesCat. No.: HY-160438CAS No.: 3003834-30-5PBX-7011 is an active camptothecin (HY-16560) derivative. PBX-7011 can bind to the DDX5 protein in cells, thereby inducing cell death through DDX5 protein degradation.
-
PROTAC AURKB Degrader-1
0 ImagesCat. No.: HY-184329CAS No.: 3114874-73-3PROTAC AURKB Degrader-1 is a selective AURKB PROTAC degrader with a DC50 value of 0.6 nM. PROTAC AURKB Degrader-1 promotes ubiquitination and degradation of AURKB. PROTAC AURKB Degrader-1 downregulates the expression levels of chromosomal passenger complex components Borealin, INCENP, Survivin as well as the transcription factor YY1. PROTAC AURKB Degrader-1 induces G2/M phase arrest and triggers Apoptosis in cells. PROTAC AURKB Degrader-1 serves as a chemical probe for biological studies of the chromosomal passenger complex. PROTAC AURKB Degrader-1 can be used in research related to acute myeloid leukemia, colorectal cancer, and non-small cell lung cancer.
-
Flavokawain A (Standard)
0 ImagesFlavokawain A is a chalcone compound and an orally active inhibitor of PRMT5 and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer.
-
Sepantronium hydrochloride
0 ImagesCat. No.: HY-10194ACAS No.: 355406-09-6Synonyms: YM-155 hydrochloride
-
N-Hydroxyphthalimide (Standard)
0 ImagesN-Hydroxyphthalimide (Standard) is the analytical standard of N-Hydroxyphthalimide (HY-Y0396). This product is intended for research and analytical applications. N-Hydroxyphthalimide is a blocking agent and catalyst. N-Hydroxyphthalimide promotes oxidation reactions by generating PINO free radicals and activating hydrogen atom transfer processes. N-Hydroxyphthalimide reduces the expression of anti-apoptotic proteins Survivin and Bcl-xL and activates caspase 9 and caspase 3. N-Hydroxyphthalimide induces Apoptosis. N-Hydroxyphthalimide inhibits the phosphorylation of mTOR (Ser2448, Ser2481) and Akt (Ser473). N-Hydroxyphthalimide has anticancer effects against breast and colon cancer.
-
Sepantronium bromide (Standard)
0 ImagesCat. No.: HY-10194RCAS No.: 781661-94-7Synonyms: YM-155 (Standard)Sepantronium bromide (Standard) is the analytical standard of Sepantronium bromide (HY-10194). This product is intended for research and analytical applications. Sepantronium bromide (YM-155) is a survivin inhibitor with an IC50 of 0.54 nM.
-
LFS-1107
0 ImagesCat. No.: HY-157136CAS No.: 1799330-91-8
-
RO0505124
0 ImagesCat. No.: HY-118447CAS No.: 443913-79-9RO0505124 is a selective CDK4 inhibitor with an IC50 of 20 nM. RO0505124 reversibly binds the ATP pocket of the kinase. RO0505124 induces G1 phase arrest in cancer cells via reduced retinoblastoma protein (Rb) phosphorylation, blocking S phase progression. RO0505124 exhibits anti-proliferative activity against various cancer cells. RO0505124 delays mitosis, induces aberrant mitosis with lagging chromosomes, driving mitotic slippage and formation of multinucleated or micronucleated cells. RO0505124 inhibits G2/M phase accumulation of survivin and borealin. RO0505124 can be used for the research of cancer.
-
Ibulocydine
0 ImagesCat. No.: HY-116054CAS No.: 1314096-68-8Ibulocydine is an isobutyrate prodrug of the Cdk inhibitor BMK-Y101 (HY-188159), with oral activity, and exhibits IC50 values of approximately 50 nM against CDK1/CDK2, 530 nM against CDK7/cyclin H/Mat1, and 85 nM against CDK9/cyclin T. Ibulocydine reduces the phosphorylation levels of Rb, nucleolin, and RNA polymerase II CTD Ser-5 and Ser-2, downregulates the expression of Mcl-1, survivin, and XIAP, decreases MMP-9 expression, and lowers the Bcl-2/Bax ratio, activates calpain-mediated Bax cleavage, cytochrome c release, and caspase activation. Ibulocydine induces apoptosis, inhibits the growth of cancer cells and xenografts, enhances the sensitivity of cancer cells to TRAIL and radiotherapy, and blocks cancer cell metastasis. Ibulocydine can be used in research related to various cancers, including hepatocellular carcinoma, triple-negative breast cancer, lung cancer, and colon cancer.
